Want to see HK:9688 full AI Analyst Report?
9688 Stock Chart & Stats
HK$18.27
-HK$0.02(-0.10%)
At close: 4:00 PM EST
HK$18.27
-HK$0.02(-0.10%)
Day’s Range― - ―
52-Week RangeHK$12.31 - HK$28.84
Previous CloseN/A
Volume1.30M
Average Volume (3M)10.12M
Market Cap
HK$21.04B
Enterprise ValueHK$12.52K
Total Cash (Recent Filing)HK$617.52M
Total Debt (Recent Filing)HK$254.58M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 10, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding1,137,828,000
10 Day Avg. Volume10,854,931
30 Day Avg. Volume10,116,373
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.68
Price to Sales (P/S)4.17
P/FCF Ratio-12.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$27.43Price Target Upside50.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.7
Revenue Forecast (FY)HK$3.40B
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsSustained ~58% gross margin indicates durable product-level economics and pricing power in specialty medicines. Over 2–6 months this margin buffer helps preserve gross profit as sales fluctuate and supports reinvestment in clinical programs and commercialization when revenue recovers.
Moderate Leverage / Supportive Balance SheetA debt-to-equity near 0.35 signals moderate leverage and a balance sheet able to support ongoing R&D and commercialization needs without excessive immediate refinancing pressure. This structural capacity gives management time to execute pipeline milestones or secure partnership funding.
Diversified Commercial And Partnership Revenue ModelMixing direct product sales with collaboration, licensing, milestone and royalty streams reduces reliance on a single asset. Structurally this business model smooths cash inflows, enables access to external innovation, and lowers program-level risk over the medium term.
Bears Say
Severe TTM Revenue ContractionAn ~81% TTM revenue decline materially erodes scale and commercial momentum, weakening the company’s ability to absorb fixed costs and leverage its healthy gross margins. Over months this constriction pressures commercialization capacity, partner negotiations, and long-term recovery prospects.
Persistent Negative Cash Flow / Cash BurnOngoing negative OCF and FCF of roughly -127M/-135M means the business still consumes cash and is not self-financing. Even if burn is improving, continued deficits over 2–6 months force reliance on external financing or milestone receipts, constraining strategic flexibility.
Meaningful Net Losses And Negative ReturnsA ~-39% net margin and ~-24% ROE reflect sustained unprofitability and poor capital returns. Structurally this limits retained earnings for reinvestment, increases dependence on raises or partners, and heightens execution risk until revenue and operating margins markedly improve.
Zai Lab Ltd News
9688 FAQ
What was Zai Lab Ltd’s price range in the past 12 months?
Zai Lab Ltd lowest stock price was HK$12.31 and its highest was HK$28.84 in the past 12 months.
What is Zai Lab Ltd’s market cap?
Zai Lab Ltd’s market cap is HK$21.04B.
When is Zai Lab Ltd’s upcoming earnings report date?
Zai Lab Ltd’s upcoming earnings report date is Nov 10, 2026 which is in 89 days.
How were Zai Lab Ltd’s earnings last quarter?
Zai Lab Ltd released its earnings results on Aug 06, 2026. The company reported -HK$0.392 earnings per share for the quarter, beating the consensus estimate of -HK$0.545 by HK$0.153.
Is Zai Lab Ltd overvalued?
According to Wall Street analysts Zai Lab Ltd’s price is currently Undervalued.
Does Zai Lab Ltd pay dividends?
Zai Lab Ltd does not currently pay dividends.
What is Zai Lab Ltd’s EPS estimate?
Zai Lab Ltd’s EPS estimate is -0.41.
How many shares outstanding does Zai Lab Ltd have?
Zai Lab Ltd has 1,137,828,000 shares outstanding.
What happened to Zai Lab Ltd’s price movement after its last earnings report?
Zai Lab Ltd reported an EPS of -HK$0.392 in its last earnings report, beating expectations of -HK$0.545. Following the earnings report the stock price went up 0.763%.
Which hedge fund is a major shareholder of Zai Lab Ltd?
Currently, no hedge funds are holding shares in HK:9688
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zai Lab Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$27.43 (50.16% Upside)
HK$27.43 (50.16% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.20%
Trailing 12-Months
Company Description
Zai Lab Ltd
Zai Lab Limited, established in 2013 and based in Shanghai, China, is a biopharmaceutical company dedicated to developing and bringing to market innovative medical treatments. Its core focus spans oncology, autoimmune diseases, infectious diseases, and neurological conditions, primarily serving patients in Mainland China and Hong Kong. The company's portfolio of commercialized products includes Zejula, an oral, once-daily poly polymerase 1/2 inhibitor; Optune, a non-invasive device employing tumor treating fields; NUZYRA for addressing acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Zai Lab also maintains a robust pipeline of investigational therapies. This pipeline features numerous oncology assets such as Odronextamab for various lymphomas, Repotrectinib—a tyrosine kinase inhibitor targeting ROS1 and TRK fusions, Margetuximab for breast and gastroesophageal cancers, Adagrasib for KRAS-G12C-mutated solid tumors, and Bemarituzumab for gastric and gastroesophageal junction cancers. Other notable pipeline candidates include CLN-081 for specific non-small cell lung cancers, multi-targeted kinase inhibitors like Elzovantinib, several monoclonal antibodies (e.g., Tebotelimab, Retifanlimab, ZL-1201), and immune modulators such as Efgartigimod for reducing disease-causing IgG antibodies and ZL-1102 targeting IL-17A. Additionally, the company is advancing therapies like KarXT for psychiatric and neurological disorders, novel EGFR inhibitors (ZL-2313, ZL-2314), a CDC7 kinase inhibitor (ZL-2309), and Sulbactam/durlobactam for serious Acinetobacter infections, showcasing its commitment to a broad range of therapeutic innovations.
9688 Stock 12 Month Forecast
Average Price Target
HK$27.43
▲(50.16% Upside)
Technical Analysis
InnoCare Pharma Ltd.
―
Everest Medicines Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―